Archive Newsletter
-
03.11.24 -- Overcoming Advanced Therapy Development Hurdles
3/11/2024
03/11/24 Cell & Gene Newsletter
-
03.11.24 -- Cell And Gene: Regulating Rare Disease Study Design
3/11/2024
03/11/24 Cell & Gene Newsletter
-
03.08.24 -- New Episodes: Yescarta's Reduced Median Turnaround Time, Inhalable mRNA and more!
3/8/2024
03/08/24 Cell & Gene Newsletter
-
03.08.24 -- Cell & Gene Best Of February
3/8/2024
03/08/24 Cell & Gene Newsletter
-
03.07.24 -- The Future of Rare Diseases
3/7/2024
03/07/24 Cell & Gene Newsletter
-
03.06.24 -- A New Approach To Allogeneic Cell Therapy Process Development
3/6/2024
03/06/24 Cell & Gene Newsletter
-
03.06.24 -- Improving Safety, Efficacy Of Source Material Collection With Automation
3/6/2024
03/06/24 Cell & Gene Newsletter
-
03.05.24 -- New CRISPR Delivery Methods, Next-Generation Plasmid Vectors, And RNP Analytics For Reduced Off-Target Effects
3/5/2024
03/05/24 Cell & Gene Newsletter
-
03.05.24 -- Amtagvi Approval: Mass General Cancer Center Weighs In
3/5/2024
03/05/24 Cell & Gene Newsletter
-
03.04.24 -- Explore Options For A More Productive Cell Banking Process
3/4/2024
03/04/24 Cell & Gene Newsletter
This website uses cookies to ensure you get the best experience on our website. Learn more